<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353495</url>
  </required_header>
  <id_info>
    <org_study_id>009-BIO-001</org_study_id>
    <nct_id>NCT01353495</nct_id>
  </id_info>
  <brief_title>Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers</brief_title>
  <official_title>A Prospective, Randomized Comparative Parallel Study of Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wright Medical Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wright Medical Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Have indolent diabetic ulcers completely healed by the Acellular Porcine Dermal Matrix (APM)&#xD;
      in 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is time -to - healing with wound size determination at 12&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Wound evaluated and granulation described by wound tracing and photographs which will be measures in wound width x length x depth at each week for 12 weeks or until full granulation has occurred in addition to the size of the wound</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>APM Graft (BIOTAPE XMTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>graft applied to wound q 3 weeks for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard wound care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wound debridement and gels and foams applied to wound weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>APM Graft (BIOTAPE XMTM)</intervention_name>
    <description>Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.</description>
    <arm_group_label>APM Graft (BIOTAPE XMTM</arm_group_label>
    <other_name>BIOTAPE XMTM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Wound Debridement</intervention_name>
    <description>Wounds debrided in both arms of study</description>
    <arm_group_label>APM Graft (BIOTAPE XMTM</arm_group_label>
    <arm_group_label>standard wound care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria and Population:&#xD;
&#xD;
          -  Male or female age 18 or older&#xD;
&#xD;
          -  Informed consent must be obtained&#xD;
&#xD;
          -  Patient's ulcer must be diabetic in origin and larger than 1cm2. Debridement will be&#xD;
             done prior to randomization. Subject's informed consent for participating in this&#xD;
             study, must be obtained prior to proceeding with sharp debridement.&#xD;
&#xD;
          -  Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes&#xD;
             mellitus per ADA).&#xD;
&#xD;
          -  Patient's ulcer must exhibit no clinical signs of infection.&#xD;
&#xD;
          -  Patient is of legal consenting age.&#xD;
&#xD;
          -  Patient is willing to provide informed consent and is willing to participate in all&#xD;
             procedures and follow up evaluations necessary to complete the study.&#xD;
&#xD;
          -  Patient has adequate circulation to the affected extremity, as demonstrated by one of&#xD;
             the following within the past 60 days:&#xD;
&#xD;
               -  Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg, OR&#xD;
&#xD;
               -  ABIs with results of ≥0.7 and ≤1.2, OR&#xD;
&#xD;
               -  Doppler arterial waveforms,which are triphasicor biphasic at the ankle of&#xD;
                  affected leg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with an ulcer probing to bone (UT Grade IIIA-D). A positive&#xD;
             probe-to-bone will be confirmed when bone or joint can be felt with a sterile,&#xD;
             ophthalmological probe.&#xD;
&#xD;
          -  Patients whose index diabetic foot ulcers are greater than 25cm2.&#xD;
&#xD;
          -  Patients considered not in reasonable metabolic control, confirmed by an HgA1c greater&#xD;
             than 12% within previous 90 days,&#xD;
&#xD;
          -  Patients whose serum creatinine levels are 3.0mg/dl or greater.&#xD;
&#xD;
          -  Patients with a known history of poor compliance with medical treatments.&#xD;
&#xD;
          -  Patients who have been previously randomized into this study, or are presently&#xD;
             participating in another clinical trial&#xD;
&#xD;
          -  Patients who are currently receiving radiation therapy or chemotherapy.&#xD;
&#xD;
          -  Patients with known or suspected local skin malignancy to the index diabetic ulcer.&#xD;
&#xD;
          -  Patients on anticoagulant medication will as in any surgical procedure, be monitored&#xD;
             According to the protocols employed at the enrolling center.&#xD;
&#xD;
          -  Patients diagnosed with autoimmune connective tissues diseases.&#xD;
&#xD;
          -  Nonrevascularable surgical sites&#xD;
&#xD;
          -  Active infection at site&#xD;
&#xD;
          -  Sensitivity to the following antibiotics: Gentamicin, Cefoxilin, Linocmycin, Polymyxin&#xD;
             B, Vancomycin&#xD;
&#xD;
          -  Any pathology that would limit the blood supply and compromise healing;&#xD;
&#xD;
          -  Patients that have received a biomedical or topical growth factor for their wound&#xD;
             within the previous 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jagpreet Mukker, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Foot Care and Clinincal Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Foot Care and Clinincal Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Education &amp; Research Institute</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2011</study_first_posted>
  <results_first_submitted>May 27, 2014</results_first_submitted>
  <results_first_submitted_qc>May 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2021</results_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Foot Ulcers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>subjects with diabetic wound ulcers were recruited for this study in podiatric wound clinic offices for treatment with the graft or standard wound care. Dates of first enrolled subject was 2010</recruitment_details>
      <pre_assignment_details>an ulcer (UT Grade IIIA-D) index ulcers &gt; than 25cm2 an HgA1c &gt; 12% within previous 90 days, serum cr 3.0mg/dl known history non-compliance previously into this study, or are in another trial receiving radiation therapy,chemotherapy. known local skin malignancy to the index diabetic ulcer. on anticoagulant medication</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Wound Care</title>
          <description>Standard Wound care (gels, foams, dressings.)&#xD;
Wound Debridement : Wounds debrided in both arms of study</description>
        </group>
        <group group_id="P2">
          <title>Treatment With Study Device</title>
          <description>Treatment with Biotape Acelular Dermis Graft&#xD;
APM Graft (BIOTAPE XMTM) : Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.&#xD;
Wound Debridement : Wounds debrided in both arms of study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Wound Care</title>
          <description>Standard Wound care (gels, foams, dressings.)&#xD;
Wound Debridement : Wounds debrided in both arms of study</description>
        </group>
        <group group_id="B2">
          <title>Treatment With Study Device</title>
          <description>Treatment with Biotape Acelular Dermis Graft&#xD;
APM Graft (BIOTAPE XMTM) : Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.&#xD;
Wound Debridement : Wounds debrided in both arms of study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth</title>
        <description>Wound evaluated and granulation described by wound tracing and photographs which will be measures in wound width x length x depth at each week for 12 weeks or until full granulation has occurred in addition to the size of the wound</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Study Device</title>
            <description>Treatment with Biotape Acelular Dermis Graft&#xD;
APM Graft (BIOTAPE XMTM) : Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.&#xD;
Wound Debridement : Wounds debrided in both arms of study</description>
          </group>
          <group group_id="O2">
            <title>Standard Wound Care</title>
            <description>Standard Wound care (gels, foams, dressings.)&#xD;
Wound Debridement : Wounds debrided in both arms of study</description>
          </group>
        </group_list>
        <measure>
          <title>Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth</title>
          <description>Wound evaluated and granulation described by wound tracing and photographs which will be measures in wound width x length x depth at each week for 12 weeks or until full granulation has occurred in addition to the size of the wound</description>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="NA">data not available as the PI left the institution. Every attempt was made to locate the data,</measurement>
                    <measurement group_id="O2" value="3.33" spread="NA">data not available as the PI left the institution. Every attempt was made to locate the data,</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Wound Care</title>
          <description>Standard Wound care (gels, foams, dressings.)&#xD;
Wound Debridement : Wounds debrided in both arms of study</description>
        </group>
        <group group_id="E2">
          <title>Treatment With Study Device</title>
          <description>Treatment with Biotape Acelular Dermis Graft&#xD;
APM Graft (BIOTAPE XMTM) : Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.&#xD;
Wound Debridement : Wounds debrided in both arms of study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="020"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <description>SUBJECT FELL ILL DUE TO FOOD POISONING AND WAS ADMITTED FOR DEHYDRATION OVER THE WEEKEND.&#xD;
reported as unrelated to device or procedure&#xD;
Outcome: resolved</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <description>SUBJECT FELL ILL DUE TO FOOD POISONING ADMITTED FOR DEHYDRATION OVER THE WEEKEND.&#xD;
Reported as not related to device or procedure final outcome resolved.&#xD;
One foot standard of care other Biotape used</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>LT HEEL PAIN WITH POSSIBLE ABSCCESS</sub_title>
                <description>DEVELOPING PAIN LEFT HEEL OVER PAST FEW DAys; MILD FOWL ODOR &amp;TENDERNESS. ? INFECTION IN THE HEEL.&#xD;
Reported as possibly related to procedure Final report was resolved</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>RT FOOT INFECTION WITH OSTEOMYELITIS</sub_title>
                <description>TO HOSPITAL. CELLULITIS RT LEG, FOOT, WAS PLACED ON IV ABX, BONE SCAN ; POSITIVE OSTEOMYELITIS.&#xD;
Reported as possibly related to procedure final eport: resolved&#xD;
reported as possibly related to the device; then reported as resolved</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>CELLULITIS TO THE RIGHT FOOT.</sub_title>
                <description>SUBJECT HAVING FEVER, CHILLES, AND PAIN. Reported: not related to device or procedure final report: resolved</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>SHORTNESS OF BREATH</sub_title>
                <description>PT STARTED EXPERIENCING INCREASING SOB AND COUGHING AND DECIDED TO GO TO ER TO ENSURE NOTHING WAS WRONG.&#xD;
Not related to the device or the procedure&#xD;
Outcome Resolved</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <description>SUBJECT WAS HAVING PROBLEM BREATHING Reported as mild Reported as unrelated to device or procedure Reported as Ongoing at the end of the study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonette Hodge, MSN, RN, CCRP, Director, Medical Affairs</name_or_title>
      <organization>Wright Medical Technology, Inc.</organization>
      <phone>8002387188 ext 4747</phone>
      <email>jonette.hodge@wmt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

